New combo therapy shows promise for hard-to-treat GIST
NCT ID NCT04258956
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 23 times
Summary
This study tested a combination of two drugs, avelumab and axitinib, in 58 adults with advanced GIST that had stopped responding to standard treatments like imatinib and sunitinib. The goal was to see if the combination could keep the cancer from growing for at least 3 months. The approach aims to control the disease rather than cure it, as ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Maria Sklodowska-Curie National Research Institue of Oncology
Warsaw, 02-781, Poland
Conditions
Explore the condition pages connected to this study.